Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →
| Demonstração de resultados | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receita total | ₹332.8B | ₹353.5B | ₹325.5B | ₹279.2B | ₹245.9B | ₹214.4B | ₹2.6B | ₹174.6B | ₹153.9B | ₹142.0B | ₹140.8B | ₹154.7B | ₹148.2B | ₹132.2B | ₹116.3B | ₹96.7B | ₹74.7B | ₹70.3B | ₹69.4B | ₹50.0B | ₹65.2B |
| Lucro bruto | ₹166.9B | ₹186.5B | ₹190.4B | ₹163.6B | ₹139.3B | ₹113.8B | ₹1.3B | ₹94.0B | ₹83.4B | ₹76.3B | ₹78.4B | ₹92.3B | ₹85.4B | ₹75.8B | ₹60.6B | ₹53.3B | ₹40.3B | ₹36.3B | ₹36.5B | ₹25.4B | ₹30.9B |
| Margem Bruta % | 50.1% | 52.8% | 58.5% | 58.6% | 56.7% | 53.1% | 50.8% | 53.8% | 54.2% | 53.7% | 55.6% | 59.7% | 57.6% | 57.4% | 52.1% | 55.1% | 53.9% | 51.7% | 52.6% | 50.8% | 47.4% |
| Resultado Operacional (EBIT) | ₹35.2B | ₹48.9B | ₹71.8B | ₹67.7B | ₹57.1B | ₹29.5B | ₹431M | ₹16.0B | ₹20.9B | ₹11.9B | ₹13.5B | ₹29.6B | ₹26.3B | ₹26.0B | ₹21.1B | ₹18.3B | ₹12.6B | ₹2.0B | (₹2.8B) | ₹3.4B | ₹11.3B |
| % de margem operacional | 10.6% | 13.8% | 22.1% | 24.3% | 23.2% | 13.8% | 16.9% | 9.2% | 13.6% | 8.4% | 9.6% | 19.1% | 17.7% | 19.7% | 18.2% | 18.9% | 16.9% | 2.9% | -4.1% | 6.7% | 17.2% |
| Resultado líquido | ₹33.2B | ₹45.1B | ₹56.5B | ₹55.7B | ₹45.1B | ₹23.6B | ₹232M | ₹19.5B | ₹18.8B | ₹9.8B | ₹12.0B | ₹20.0B | ₹22.2B | ₹21.5B | ₹16.8B | ₹14.3B | ₹11.0B | ₹1.1B | (₹5.2B) | ₹4.7B | ₹9.3B |
| Margem Líquida % | 10.0% | 12.8% | 17.4% | 20.0% | 18.3% | 11.0% | 9.1% | 11.2% | 12.2% | 6.9% | 8.6% | 12.9% | 15.0% | 16.3% | 14.4% | 14.7% | 14.8% | 1.5% | -7.4% | 9.4% | 14.3% |
| EBITDA | ₹55.6B | ₹83.3B | ₹96.7B | ₹88.4B | ₹74.4B | ₹45.1B | ₹535M | ₹41.8B | ₹35.5B | ₹23.6B | ₹24.8B | ₹39.9B | ₹34.4B | ₹33.1B | ₹22.5B | ₹20.3B | ₹16.8B | ₹6.6B | ₹1.5B | ₹7.3B | ₹14.3B |
| Lucro por ação (EPS) | ₹39.81 | ₹54.11 | ₹67.77 | ₹66.80 | ₹54.17 | ₹28.34 | ₹0.28 | ₹23.48 | ₹22.62 | ₹11.80 | ₹14.42 | ₹23.40 | ₹25.95 | ₹25.21 | ₹19.69 | ₹16.76 | ₹12.99 | ₹1.26 | ₹-6.14 | ₹5.55 | ₹11.74 |
| Ações em circulação (M) | 833M | 833M | 834M | 834M | 832M | 832M | 832M | 830M | 831M | 831M | 835M | 855M | 855M | 853M | 852M | 851M | 850M | 848M | 842M | 843M | 796M |
Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.
Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de RDY. /companies/us/RDY
As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.
About TickerBase · Data methodology & sources · Privacy · Terms